tradingkey.logo

Merck & Co Inc

MRK
121.930USD
+2.130+1.78%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
303.28BValor de mercado
16.75P/L TTM

Merck & Co Inc

121.930
+2.130+1.78%

Mais detalhes de Merck & Co Inc Empresa

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Informações de Merck & Co Inc

Código da empresaMRK
Nome da EmpresaMerck & Co Inc
Data de listagemFeb 06, 2077
CEODavis (Robert M)
Número de funcionários75000
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 06
Endereço126 East Lincoln Avenue
CidadeRAHWAY
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal07065
Telefone19087404000
Sitehttps://www.merck.com/
Código da empresaMRK
Data de listagemFeb 06, 2077
CEODavis (Robert M)

Executivos da empresa Merck & Co Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
491.04K
+47434.00%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
199.21K
+13880.00%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
100.06K
+20469.00%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
95.21K
+9865.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
65.00K
+11583.00%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
28.61K
+5703.00%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
491.04K
+47434.00%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
199.21K
+13880.00%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
100.06K
+20469.00%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
95.21K
+9865.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
65.00K
+11583.00%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
28.61K
+5703.00%

Detalhamento da receita

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
10.01B
0.00%
Europe, Middle East and Africa
3.68B
0.00%
Latin America
905.00M
0.00%
Other
798.00M
0.00%
Asia Pacific (Other than China and Japan)
764.00M
0.00%
Outro
-16.16B
100.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.20%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Outro
73.91%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.20%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Outro
73.91%
Tipos de investidores
Investidores
Proporção
Investment Advisor
42.26%
Investment Advisor/Hedge Fund
26.83%
Research Firm
3.18%
Pension Fund
2.50%
Bank and Trust
2.13%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.05%
Insurance Company
0.68%
Family Office
0.15%
Outro
19.66%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
5411
1.99B
80.21%
-57.82M
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
250.94M
10.11%
-809.74K
-0.32%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
141.15M
5.69%
-1.64M
-1.15%
Sep 30, 2025
State Street Investment Management (US)
118.18M
4.76%
-313.69K
-0.26%
Sep 30, 2025
Wellington Management Company, LLP
75.28M
3.03%
-1.58M
-2.05%
Sep 30, 2025
Geode Capital Management, L.L.C.
59.80M
2.41%
+846.19K
+1.44%
Sep 30, 2025
Charles Schwab Investment Management, Inc.
53.70M
2.16%
-166.01K
-0.31%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
27.61M
1.11%
-866.46K
-3.04%
Sep 30, 2025
Fisher Investments
24.07M
0.97%
-945.57K
-3.78%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
22.50M
0.91%
-281.91K
-1.24%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
VanEck Pharmaceutical ETF
16.09%
FT Vest DJIA Dogs 10 Target Income ETF
10.79%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
6.94%
First Trust Morningstar Dividend Leaders Index Fund
5.39%
Coastal Compass 100 ETF
5.13%
Invesco Pharmaceuticals ETF
4.96%
VanEck Morningstar Wide Moat Value ETF
4.73%
Vaneck Durable High Dividend ETF
4.65%
Franklin Income Focus ETF
4.56%
Ver Mais
VanEck Pharmaceutical ETF
Proporção16.09%
FT Vest DJIA Dogs 10 Target Income ETF
Proporção10.79%
First Trust NASDAQ Pharmaceuticals ETF
Proporção7.94%
Invesco Dow Jones Industrial Average Dividend ETF
Proporção6.94%
First Trust Morningstar Dividend Leaders Index Fund
Proporção5.39%
Coastal Compass 100 ETF
Proporção5.13%
Invesco Pharmaceuticals ETF
Proporção4.96%
VanEck Morningstar Wide Moat Value ETF
Proporção4.73%
Vaneck Durable High Dividend ETF
Proporção4.65%
Franklin Income Focus ETF
Proporção4.56%

Dividendo

Um total de 28.91B USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Nov 18, 2025
MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025
Dec 15, 2025
Jan 08, 2026
Dec 15, 2025
Jul 22, 2025
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Oct 07, 2025
Sep 15, 2025
May 27, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025
Jun 16, 2025
Jul 08, 2025
Jun 16, 2025
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
Ver Mais

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI